$SPPI (Spectrum Pharmaceuticals, Inc.)

$SPPI {{ '2015-12-16T15:40:24+0000' | timeago}} • Announcement

Biotech company $SPPI said it has reached an agreement with the US FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012 (eflapegrastim), a novel, long acting G-CSF in patients with breast cancer. $SPPI expects to start the pivotal trial shortly and plans to complete enrollment in 2017.

$RAD {{ '2017-09-19T15:31:35+0000' | timeago}} • Announcement

Under the amended and restated asset purchase agreement with $RAD, $WBA does not expect the transaction to have a significant impact to its adjusted EPS in FY17. $WBA also expects to realize annual synergies from the transaction of more than $300MM, which are expected to be fully realized within four years of the initial closing of the transaction.

$MDXG {{ '2017-09-19T15:22:20+0000' | timeago}} • Announcement

$MDXG has filed with the FDA to initiate its Investigational New Drug (IND) Phase 2 clinical trial for osteoarthritis of the knee. The objective is to determine the safety and effectiveness of AmnioFix Injectable as compared to the 0.9% Sodium Chloride USP placebo injection control for the treatment of knee osteoarthritic pain.

$WBA {{ '2017-09-19T14:19:18+0000' | timeago}} • Announcement

Drugstore chain $WBA, in its fourth attempt, clinched regulatory approval to buy 1,932 stores, 3 distribution centers and related inventory from $RAD for $4.375Bil. The new deal has 250 fewer stores than the earlier deal & is lower than the previous proposal of $5.18Bil. Store purchases would begin in Oct., with completion expected in spring 2018.

$NEOG {{ '2017-09-19T13:40:41+0000' | timeago}} • Announcement

During 1Q18, $NEOG's Animal Safety segment revenue increased 9% YoY, driven by significant growth in its genomics business. Revenues from Worldwide animal genomics business increased 29% from a year earlier. The rise was basically due to increased market share in the global cattle and poultry markets.

$NEOG {{ '2017-09-19T13:39:04+0000' | timeago}} • Announcement

Food safety company $NEOG reported a 20.57% increase in its 1Q18 earnings, driven by a revenue jump of 13.88% in the quarter. Net income rose to $11.91MM, or $0.31 per share from $9.88MM, or $0.26 per share a year earlier. Revenue rose to $95.25MM from $83.64MM a year ago.

$EVHC {{ '2017-09-19T12:30:35+0000' | timeago}} • Announcement

As part of $EVHC's organizational changes, Karey Witty, a veteran healthcare executive, has been appointed to the new role of EVP and COO, effective Oct 2, 2017. Kevin Eastridge, currently CAO, will succeed Claire Gulmi as CFO, effective same day.

$EVHC {{ '2017-09-19T12:24:50+0000' | timeago}} • Announcement

$EVHC announced the authorization of a program to repurchase up to $250MM of its common stock, which represents approx 4% of its current market capitalization.

$ALXN {{ '2017-09-14T20:51:47+0000' | timeago}} • Announcement

Biopharmaceutical company $ALXN named Paul Friedman to its board of directors. Friedman had served as President and CEO of Incyte Corp. from 2001 to 2014. He succeeds Douglas Norby, who retired after serving on Alexion's board for 18 years. The company said Alvin Parven has decided not to stand for re-election as director.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$MDXG {{ '2017-09-13T13:59:54+0000' | timeago}} • Announcement

$MDXG said its production operations in Georgia and placenta recovery functions are operating normally, and its previously published expectation for 3Q17 revenue to exceed the $80MM mark is unaffected by Hurricane Irma. $MDXG remains confident in its ability to meet or exceed revenue projections for 2017, which are at $309-311MM range.

$ALXN {{ '2017-09-12T13:18:41+0000' | timeago}} • Announcement

$ALXN has charted out a re-alignment plan, with its refocused corporate strategy. The initiative is expected to deliver annual pre-tax savings of about $270MM (GAAP) and $250MM (non-GAAP) by 2019. The restructuring will reduce the company's workforce by 20%. The total pre-tax restructuring expenses are expected to be between $340MM and $440MM.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

Recent Transcripts

ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
TSRO (Tesaro, Inc.)
Tuesday, August 8 2017 - 8:15pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
CTIC (CTI BioPharma Corp.)
Thursday, August 3 2017 - 8:30pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 9:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, August 1 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
MDXG (MiMedx Group, Inc.)
Thursday, July 27 2017 - 2:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm

AlphaGraphics you may like